50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
How You Should Be Choosing Your Stocks (Ad)pixel
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
How You Should Be Choosing Your Stocks (Ad)pixel
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
How You Should Be Choosing Your Stocks (Ad)pixel
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
How You Should Be Choosing Your Stocks (Ad)pixel
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
How You Should Be Choosing Your Stocks (Ad)pixel
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
How You Should Be Choosing Your Stocks (Ad)pixel
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
How You Should Be Choosing Your Stocks (Ad)pixel
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
How You Should Be Choosing Your Stocks (Ad)pixel
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
How You Should Be Choosing Your Stocks (Ad)pixel
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
How You Should Be Choosing Your Stocks (Ad)pixel
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
How You Should Be Choosing Your Stocks (Ad)pixel
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
How You Should Be Choosing Your Stocks (Ad)pixel
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
NASDAQ:AXLA

Axcella Health - AXLA Stock Forecast, Price & News

$1.62
0.00 (0.00%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.55
$1.67
50-Day Range
$1.62
$2.73
52-Week Range
$1.35
$4.40
Volume
11,751 shs
Average Volume
74,667 shs
Market Capitalization
$85.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.80

Axcella Health MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
319.8% Upside
$6.80 Price Target
Short Interest
Healthy
0.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of Axcella Health in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1,378 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.55) to ($1.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

190th out of 1,071 stocks

Biological Products, Except Diagnostic Industry

28th out of 172 stocks

AXLA stock logo

About Axcella Health (NASDAQ:AXLA) Stock

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Receive AXLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter.

AXLA Stock News Headlines

Axcella Awaits Interim Data From EMMPACT NASH Study
Axcella Health: Q2 Earnings Insights
The Petri Dish: Axcella advances long Covid drug
Axcella Health: Revisiting A Lottery Ticket
See More Headlines
Receive AXLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter.

AXLA Company Calendar

Last Earnings
8/12/2022
Today
9/27/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXLA
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.80
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+319.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-64,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.56 per share

Miscellaneous

Free Float
49,159,000
Market Cap
$85.17 million
Optionable
Not Optionable
Beta
1.10

Key Executives

  • Mr. William R. Hinshaw Jr.Mr. William R. Hinshaw Jr. (Age 53)
    Pres, CEO & Director
    Comp: $830.23k
  • Dr. Alison D. Schecter M.D. (Age 58)
    Pres of Strategy & Operations
    Comp: $525.53k
  • Mr. Laurent Chardonnet (Age 57)
    Consultant
    Comp: $415k
  • Mr. Robert W. Crane (Age 63)
    Sr. VP & CFO
  • Dr. Paul Fehlner J.D. (Age 58)
    Ph.D., Sr. VP, Chief Legal Officer & Corp. Sec.
  • Ms. Virginia R. Dean (Age 56)
    Sr. VP & Chief People Officer
  • Dr. Larry Bell
    Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP
  • Dr. Margaret James Koziel M.D. (Age 62)
    Sr. VP & Chief Medical Officer
  • Mr. Dan Kirby
    Sr. VP of Strategic Operations
  • Mr. Karim Azer Ph.D.
    VP of Systems Biology & Discovery













AXLA Stock - Frequently Asked Questions

Should I buy or sell Axcella Health stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXLA shares.
View AXLA analyst ratings
or view top-rated stocks.

What is Axcella Health's stock price forecast for 2022?

5 equities research analysts have issued 1 year price objectives for Axcella Health's shares. Their AXLA share price forecasts range from $6.00 to $8.00. On average, they expect the company's share price to reach $6.80 in the next twelve months. This suggests a possible upside of 319.8% from the stock's current price.
View analysts price targets for AXLA
or view top-rated stocks among Wall Street analysts.

How have AXLA shares performed in 2022?

Axcella Health's stock was trading at $2.09 at the beginning of 2022. Since then, AXLA shares have decreased by 22.5% and is now trading at $1.62.
View the best growth stocks for 2022 here
.

When is Axcella Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our AXLA earnings forecast
.

How were Axcella Health's earnings last quarter?

Axcella Health Inc. (NASDAQ:AXLA) issued its quarterly earnings data on Friday, August, 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.04.

What is Bill Hinshaw's approval rating as Axcella Health's CEO?

5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend.

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).

When did Axcella Health IPO?

(AXLA) raised $76 million in an initial public offering on Thursday, May 9th 2019. The company issued 3,600,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

What is Axcella Health's stock symbol?

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Who are Axcella Health's major shareholders?

Axcella Health's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Pinnacle Private Wealth LLC (0.12%), Renaissance Technologies LLC (0.11%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Catherine A Sohn, David R Epstein, Des Produits Nestle S Societe, Laurent Chardonnet, Manu Chakravarthy, Margaret Koziel, Paul Fehlner, Robert Crane, Ventures Fund Iv LP Flagship and William Hinshaw.
View institutional ownership trends
.

How do I buy shares of Axcella Health?

Shares of AXLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axcella Health's stock price today?

One share of AXLA stock can currently be purchased for approximately $1.62.

How much money does Axcella Health make?

Axcella Health (NASDAQ:AXLA) has a market capitalization of $85.17 million. The company earns $-64,630,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis.

How can I contact Axcella Health?

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.axcellahealth.com. The company can be reached via phone at (857) 320-2200, via email at ir@axcellahealth.com, or via fax at 617-441-6243.

This page (NASDAQ:AXLA) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.